The global regenerative medicine market size is expected to reach USD 5.60 billion by 2025, expanding at a CAGR of 11.6% over the forecast period -…

NEW YORK, Oct. 21, 2019 /PRNewswire/ --

Regenerative Medicine Market Size, Share & Trends Analysis By Product (Primary Cell-based, Stem & Progenitor Cell-based), By Therapeutic Category (Dermatology, Oncology) And Segment Forecasts, 2019 - 2025

Read the full report: https://www.reportlinker.com/p05807250/?utm_source=PRN

The global regenerative medicine market size is expected to reach USD 5.60 billion by 2025, expanding at a CAGR of 11.6% over the forecast period. Regenerative medicines are expected to have a significant impact in healthcare to treat specific indications and chronic conditions. Therefore, high prevalence of cancer, neurodegenerative, orthopedic, and other aging-associated disorders coupled with increasing global geriatric population is driving the market growth. Moreover, rising prevalence of inheritable genetic diseases is anticipated to fuel the demand in the field of biotechnology field.

Market players are engaged in implementing novel protocols for the release of novel therapeutics. For instance, in July 2018, Convelo Therapeutics launched regenerative medicines for the treatment of various neurological diseases, such as multiple sclerosis.Agreements models initiated by the companies coupled with commercialization in emerging countries fuels the growth. For instance, in March 2018, Hitachi Chemical signed an agreement with the Daiichi Sankyo and SanBio Group to conduct clinical manufacturing of regenerative medicines developed by respective companies for Japanese and U.S. markets.

Regenerative medicine is anticipated to witness great attention in healthcare sector due to its wide range of applications and significant advancements tissue engineering, stem cells, gene therapy, drug discovery, and nanotechnology. For example, 3D printing is preferred over scaffold with stem cells to restore structure and functional characteristics of biological specimens.

Dermatology is estimated to hold the largest market share in terms of revenue in 2018, owing to the availability of various products and their application in simple and chronic wound healing. Oncology therapeutic category on the other hand, is projected to expand at the fastest CAGR during the forecast period owing to the presence of strong pipeline of regenerative medicines for cancer treatment.

North America held the largest regenerative medicine market share in terms of revenue in 2018 and is projected to continue its dominance in near future. A significant number of universities and research organizations investigating various stem cell-based approaches for regenerative apposition in U.S. is anticipated to propel the growth.

Further key findings from the report suggest: Therapeutics emerged dominant among product segments in 2018 due to high usage of primary cell-based therapies along with advances in stem cell and progenitor cell therapies Implementation of primary cell-based therapies in dermatological, musculoskeletal, and dental application results in highest share of this segment Stem cell and progenitor cell-based therapies are anticipated to witness rapid growth due to high investments in stem cell research and increasing number of stem cell banks With rise in R&D and clinical trials, key players are offering consulting services leading to lucrative growth of the services segment Asia Pacific is projected to witness the fastest CAGR during the forecast period due to rapid adoption of cell-based approaches in healthcare and emergence of key players Key players operating in the regenerative medicine market including AstraZeneca; F Hoffmann-La Roche Ltd.; Pfizer Inc.; Merck & Co., Inc.; Integra LifeSciences Corporation; and Eli Lilly and Company

Read the full report: https://www.reportlinker.com/p05807250/?utm_source=PRN

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________Contact Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

See the original post:
The global regenerative medicine market size is expected to reach USD 5.60 billion by 2025, expanding at a CAGR of 11.6% over the forecast period -...

15 Antiviral Herbs to Keep You Healthy – Healthline

Since ancient times, herbs have been used as natural treatments for various illnesses, including viral infections.

Due to their concentration of potent plant compounds, many herbs help fight viruses and are favored by practitioners of natural medicine.

At the same time, the benefits of some herbs are only supported by limited human research, so you should take them with a grain of salt.

Here are 15 herbs with powerful antiviral activity.

Oregano is a popular herb in the mint family thats known for its impressive medicinal qualities. Its plant compounds, which include carvacrol, offer antiviral properties.

In a test-tube study, both oregano oil and isolated carvacrol reduced the activity of murine norovirus (MNV) within 15 minutes of exposure (1).

MNV is highly contagious and the primary cause of stomach flu in humans. It is very similar to human norovirus and used in scientific studies because human norovirus is notoriously difficult to grow in laboratory settings (2).

Oregano oil and carvacrol have also been shown to exhibit antiviral activity against herpes simplex virus type-1 (HSV-1); rotavirus, a common cause of diarrhea in infants and children; and respiratory syncytial virus (RSV), which causes respiratory infections (3, 4, 5).

Also a member of the mint family, sage is an aromatic herb that has long been used in traditional medicine to treat viral infections (6).

The antiviral properties of sage are mostly attributed to compounds called safficinolide and sage one, which are found in the leaves and stem of the plant (7).

Test-tube research indicates that this herb may fight human immunodeficiency virus type 1 (HIV-1), which can lead to AIDS. In one study, sage extract significantly inhibited HIV activity by preventing the virus from entering target cells (8).

Sage has also been shown to combat HSV-1 and Indiana vesiculovirus, which infects farm animals like horses, cows, and pigs (9, 10).

Many types of basil, including the sweet and holy varieties, may fight certain viral infections.

For example, one test-tube study found that sweet basil extracts, including compounds like apigenin and ursolic acid, exhibited potent effects against herpes viruses, hepatitis B, and enterovirus (11).

Holy basil, also known as tulsi, has been shown to increase immunity, which may help fight viral infections.

In a 4-week study in 24 healthy adults, supplementing with 300 mg of holy basil extract significantly increased levels of helper T cells and natural killer cells, both of which are immune cells that help protect and defend your body from viral infections (12).

Fennel is a licorice-flavored plant that may fight certain viruses.

A test-tube study showed that fennel extract exhibited strong antiviral effects against herpes viruses and parainfluenza type-3 (PI-3), which causes respiratory infections in cattle (13).

Whats more, trans-anethole, the main component of fennel essential oil, has demonstrated powerful antiviral effects against herpes viruses (14).

According to animal research, fennel may also boost your immune system and decrease inflammation, which may likewise help combat viral infections (15).

Garlic is a popular natural remedy for a wide array of conditions, including viral infections.

In a study in 23 adults with warts caused by human papillomavirus (HPV), applying garlic extract to affected areas twice daily eliminated the warts in all of them after 12 weeks (16, 17).

Additionally, older test-tube studies note that garlic may have antiviral activity against influenza A and B, HIV, HSV-1, viral pneumonia, and rhinovirus, which causes the common cold. However, current research is lacking (18).

Animal and test-tube studies indicate that garlic enhances immune system response by stimulating protective immune cells, which may safeguard against viral infections (19).

Lemon balm is a lemony plant thats commonly used in teas and seasonings. Its also celebrated for its medicinal qualities.

Lemon balm extract is a concentrated source of potent essential oils and plant compounds that have antiviral activity (20).

Test-tube research has shown that it has antiviral effects against avian influenza (bird flu), herpes viruses, HIV-1, and enterovirus 71, which can cause severe infections in infants and children (8, 20, 21, 22, 23).

Peppermint is known to have powerful antiviral qualities and commonly added to teas, extracts, and tinctures meant to naturally treat viral infections.

Its leaves and essential oils contain active components, including menthol and rosmarinic acid, which have antiviral and anti-inflammatory activity (24).

In a test-tube study, peppermint-leaf extract exhibited potent antiviral activity against respiratory syncytial virus (RSV) and significantly decreased levels of inflammatory compounds (25).

Rosemary is frequently used in cooking but likewise has therapeutic applications due to its numerous plant compounds, including oleanolic acid (26).

Oleanolic acid has displayed antiviral activity against herpes viruses, HIV, influenza, and hepatitis in animal and test-tube studies (27).

Plus, rosemary extract has demonstrated antiviral effects against herpes viruses and hepatitis A, which affects the liver (28, 29).

Echinacea is one of the most popularly used ingredients in herbal medicine due to its impressive health-promoting properties. Many parts of the plant, including its flowers, leaves, and roots, are used for natural remedies.

In fact, Echinacea purpurea, a variety that produces cone-shaped flowers, was used by Native Americans to treat a wide array of conditions, including viral infections (30).

Several test-tube studies suggest that certain varieties of echinacea, including E. pallida, E. angustifolia, and E. purpurea, are particularly effective at fighting viral infections like herpes and influenza (31).

Notably, E. purpurea is thought to have immune-boosting effects as well, making it particularly useful for treating viral infections (30).

Sambucus is a family of plants also called elder. Elderberries are made into a variety of products, such as elixirs and pills, that are used to naturally treat viral infections like the flu and common cold.

A study in mice determined that concentrated elderberry juice suppressed influenza virus replication and stimulated immune system response (32).

Whats more, in a review of 4 studies in 180 people, elderberry supplements were found to substantially reduce upper respiratory symptoms caused by viral infections (33).

Licorice has been used in traditional Chinese medicine and other natural practices for centuries.

Glycyrrhizin, liquiritigenin, and glabridin are just some of the active substances in licorice that have powerful antiviral properties (34).

Test-tube studies demonstrate that licorice root extract is effective against HIV, RSV, herpes viruses, and severe acute respiratory syndrome-related coronavirus (SARS-CoV), which causes a serious type of pneumonia (35, 36, 37).

Astragalus is a flowering herb popular in traditional Chinese medicine. It boasts Astragalus polysaccharide (APS), which has significant immune-enhancing and antiviral qualities (38).

Test-tube and animal studies show that astragalus combats herpes viruses, hepatitis C, and avian influenza H9 virus (39, 40, 41, 42).

Plus, test-tube studies suggest that APS may protect human astrocyte cells, the most abundant type of cell in the central nervous system, from infection with herpes (38).

Ginger products, such as elixirs, teas, and lozenges, are popular natural remedies and for good reason. Ginger has been shown to have impressive antiviral activity thanks to its high concentration of potent plant compounds.

Test-tube research demonstrates that ginger extract has antiviral effects against avian influenza, RSV, and feline calicivirus (FCV), which is comparable to human norovirus (43, 44, 45)

Additionally, specific compounds in ginger, such as gingerols and zingerone, have been found to inhibit viral replication and prevent viruses from entering host cells (46).

Ginseng, which can be found in Korean and American varieties, is the root of plants in the Panax family. Long used in traditional Chinese medicine, it has been shown to be particularly effective at fighting viruses.

In animal and test-tube studies, Korean red ginseng extract has exhibited significant effects against RSV, herpes viruses, and hepatitis A (47, 48, 49).

Plus, compounds in ginseng called ginsenosides have antiviral effects against hepatitis B, norovirus, and coxsackieviruses, which are associated with several serious diseases including an infection of the brain called meningoencephalitis (49).

Dandelions are widely regarded as weeds but have been studied for multiple medicinal properties, including potential antiviral effects.

Test-tube research indicates that dandelion may combat hepatitis B, HIV, and influenza (50, 51, 52).

Moreover, one test-tube study noted that dandelion extract inhibited the replication of dengue, a mosquito-borne virus that causes dengue fever. This disease, which can be fatal, triggers symptoms like high fever, vomiting, and muscle pain (53, 54).

Herbs have been used as natural remedies since ancient times.

Common kitchen herbs, such as basil, sage, and oregano, as well as lesser-known herbs like astragalus and sambucus, have powerful antiviral effects against numerous viruses that cause infections in humans.

Its easy to add these powerful herbs to your diet by using them in your favorite recipes or making them into teas.

However, keep in mind that most research has been conducted in test tubes and animals using concentrated extracts. Therefore, its unclear whether small doses of these herbs would have the same effects.

If you decide to supplement with extracts, tinctures, or other herbal products, consult your healthcare provider to ensure safe usage.

Continued here:
15 Antiviral Herbs to Keep You Healthy - Healthline

Kidney Cancer: What Is New in the Second-Line Treatment Setting? – Curetoday.com

Dr. Camillo Porta discussed what is new in kidney cancer beyond the first line of treatment at A Vision of Hope: A Kidney Cancer Educational Symposium.

BY Kristie L. Kahl

At A Vision of Hope: A Kidney Cancer Educational Symposium hosted by the Judy Nicholson Kidney Cancer Symposium and Penn Medicine Abramson Cancer Center Porta discussed what is new in kidney cancer beyond the first line of treatment.

Second-line treatment, he explained, occurs when the first line of therapy has failed in doing its job to control tumor progression. This is always a tough moment for patients with cancer, like the entire world is on the edge of falling on his/her head, Porta added. For the vast majority of you, fortunately, this is not true. This is an unpleasant, but obliged step in your personal war against cancer.

He noted that it has been clear that a benefit in overall survival has been seen among those treated with a sequence of active treatment, not just by a single agent. The number of patients receiving more than two lines of therapy is increasing and this often leads to long survival times, Porta explained.

Some treatments that have been evaluated for the second-line treatment of kidney cancer include Sutent (sunitinib), Votrient (pazopanib), Nexavar (sorafenib), Avastin (bevacizumab plus interferon, Inlyta (axitinib), Afinitor (everolimus), Lenvima (lenvatinib) plus Afinitor and Bevencio (avelumab) plus Inlyta. However, these therapeutic options have only shown a benefit in improving progression-free survival (the time from treatment to disease progression or worsening). In a subgroup of patients, Torisel (temsirolimus) monotherapy, Yervoy (ipilimumab) plus Opdivo (nivolumab) and Keytruda (pembrolizumab) plus Inlyta have prolonged overall survival in the first-line setting, while Opdivo and Cabometyx (cabozantinib) have also done so in the second-line setting.

With so many options, Porta noted that not all physicians are equal, but patients are. (Patients) simply want to live longer and better. Whatever better means to each of them, he said, adding that this is why physicians are focused on capturing quality of life in patient-reported outcomes.

The trade-off between benefits, like survival gain, and harms, like treatment-related toxicities, in the second-line setting is a trade-off a patient is willing to accept and is often different compared with things that are usually accepted by a newly diagnosed patient, Porta explained. Safety and quality of life are usually more important in later treatment lines, though. Of course, this is not a universal rule.

Therefore, the treatment experience in the second-line setting, like receiving a more gentle agent, is key in selecting which therapeutic option to use.

Luckily, renal cell carcinoma is an angiogenesis-driven tumor throughout the entirety of disease. Meaning that after the failure of an antiangiogenic agent, another can be active and continue to control disease progression, Porta said. This is a true paradigm shift from the era of cytotoxic chemotherapy.

Here is the original post:
Kidney Cancer: What Is New in the Second-Line Treatment Setting? - Curetoday.com

Artificial Early Mouse Embryos Created In The Lab Using Stems Cells Rather Than Sperm Or Eggs – IFLScience

A groundbreaking study has seen scientists create the early stages of artificial mice embryos in a lab using stem cells, rather than sperm or eggs, for the first time.

Its still very early days for the research, and it has some big problems to iron out, but itcould potentially pave the way towards creating viable embryos just from cultured cells. It could also provide scientists with an indefinite source of blastocysts to study the early stages of development, without the need for sperm, eggs, or natural embryos.

These studies will help us to better understand the very beginnings of life; how early on in life a single cell can give rise to millions of cells and how they are assembled in space and time to give rise to a fully developed organism. Importantly, this work avoids the use of natural embryos and is scalable, Juan Carlos Izpisua Belmonte, study author and professor in Salks Gene Expression Laboratory, explained in a statement.

Reporting in the journal Cell, researchers at the Salk Institute and the University of Texas Southwestern Medical Center created structures resembling mouse blastocysts, known as blastoids.

Blastocysts are structures made up of 100+ cells or so, found in the very early stages of development in mammals. After the blastocyst implants itself into the uterus, it can develop into an embryo.Typically, the blastocyst forms around five days after a sperm has fertilized an egg.

However, the researchers managed to create an early form of blastocyst using pluripotent stem cells, master cells that can turn into almost any kind of tissue in the body, obtained from adult mouse cells.The stem cells were placed together and nurtured in a special culture medium. They soon formed connections with each other, eventually forming a ball of cells with an inner and outer layer.

The structure of this, according to the researchers, was remarkably like a natural blastocyst. The artificial blastoids contained the same three primordial cell types found in natural blastocysts, along with being a similar size and similar gene expression.

Other researchers working in the field have described the research as wonderful, significant, and outstanding, although they warn there are still many hurdles to overcome before we see this research being applied.

For example, its noteworthy that the blastocyst-like structures showed signs of malformation and disorganization, meaning they wouldnt be able to develop into a fully viable embryo or mouse.

I would caution against interpreting the current study as showing that embryos can be made from adult tissues this has the potential to raise undue ethical concerns, the structures made are not embryos, and the research is in mice not humans, said Dr Harry Leitch, a stem cell biologist at the MRC London Institute of Medical Sciences and Imperial College London who was not involved in the study.

In reality, this study reports incremental findings in a pre-existing model system, and makes a valuable contribution to ongoing research in the field.

Read the original here:
Artificial Early Mouse Embryos Created In The Lab Using Stems Cells Rather Than Sperm Or Eggs - IFLScience

A stop-motion movie of the whole brain, starring new neurons – Spectrum

Cells on the move: A new technique helps reveal patterns in the migration of neurons (green) to their destination (red).

A new method visualizes nascent neurons in the mouse brain and follows them as they migrate to their final destinations.

The method essentially a time series of 3D images may shed light on processes that unfold during brain development.

We take snapshots at different time points, then match them together to see dynamic processes, says Alexander Lazutkin, senior scientist at the P.K. Anokhin Institute of Normal Physiology in Moscow, Russia. Lazutkin presented the work yesterday at the 2019 Society for Neuroscience annual meeting in Chicago, Illinois.

Researchers can use the method to study the birth of neurons and the complex ways in which they migrate through the brain. Abnormalities in these processes have been implicated in autism.

In the weeks after a mouse is born, neural stem cells in its brain continue to divide and generate neurons. Lazutkins team marked these dividing cells throughout the brain by adapting a fluorescent labeling technique typically used on thin sections of tissue. (The labeling method was published 12 September in MethodsX1.)

In the new work, they labeled cells in the brains of adult mice. They used a fluorescent microscope to take a snapshot of the whole brain of one set of animals, and then a different set of animals one day older the next day, and so on. They built an algorithm to stitch the images together and fill in the gaps to form a time series.

The result is a movie that tracks cells locations as they migrate toward their destination. The cells originate in the subventricular zone, one of two places where cells continue to divide in the adult brain. The movie shows the migrating cells reaching the olfactory bulb in about 10 days.

It also shows cells forming a stripe pattern in the subventricular zone.

We suppose these are distinct migration streams, Lazutkin says. You cant see this pattern on a conventional [2D] slide. But when you have the full picture, you can recognize them.

Lazutkin and his colleagues plan to use the method to look at differences in early brain development between typical mice and mouse models of autism particularly those with mutations that lead to altered brain growth.

For more reports from the 2019 Society for Neuroscience annual meeting, please click here.

Read more:
A stop-motion movie of the whole brain, starring new neurons - Spectrum

Humans evolved to think faster by slowing down brain development – New Scientist News

By Clare Wilson

D. ROBERTS/SCIENCE PHOTO LIBRARY

How did humans get to be so much cleverer than other apes? One counter-intuitive idea is that it was made possible by a slowdown of our brain growth during fetal development.

The suggestion comes from a relatively new approach of growing embryonic-like stem cells in a dish and coaxing them to turn into nervous system cells until they form pea-sized three-dimensional clumps known as organoids.

These mini brains seem to replicate real neuron behaviour more closely than when brain cells are grown in a flat layer. They have nothing like the complexity needed for thought or consciousness, but do develop into different kinds of brain tissue and display patterns of electrical activity that have some similarities with real brains.

Advertisement

Human brains are certainly bigger than those of our nearest primate relatives, but there are surprisingly few differences in structure. So it is unclear what gives rise to the huge differences in our mental abilities.

Gray Camp at the Max Planck Institute for Evolutionary Anthropology in Leipzig, Germany, and his colleagues used stem cells from humans, chimpanzees and macaque monkeys to make mini brains for each species. After four months, a key difference was that nerve cells in the chimp and monkey organoids were more mature.

Identifying such differences may be a step towards explaining why humans are more intelligent although the team doesnt speculate on exactly how their findings might relate to this puzzle.

Until now it wasnt possible to compare human and chimp organ development, says Camp. The organoids, some made from stem cells that can be generated directly from adult cells, offer a way of making that comparison.

Camp and his team also delved into another long-standing puzzle: why there are so few differences between the protein-coding genes of humans and the other apes, considering the huge disparity in our intellects.

A recent technique for analysing which genes are turned on or off in individual cells, known as single cell RNA sequencing, has suggested the answer might lie in differences in which genes are turned on at different times.

In the latest study, Camps team charted which genes are turned on in different brain cells over four months of mini brain development, comparing the results across humans, chimps and macaques, to make a database other researchers can also use.

Organoids are most useful for society in letting us understand disease, says Camp. But its also very interesting to think about where our species came from and how we became uniquely human.

Journal reference: Nature, DOI: 10.1038/s41586-019-1654-9

More on these topics:

Read the original post:
Humans evolved to think faster by slowing down brain development - New Scientist News

Healthcare Terms Are Out of Touch, Says Mom Advocate – Medscape

This transcript has been edited for clarity.

Eric J. Topol, MD: Hello. I'm Eric Topol, editor-in-chief for Medscape. I'm thrilled to speak with Hala Durrah today, who I got to know about through a remarkable essay she wrote for Health Affairs back in March. Hala, welcome to our program.

Hala H. Durrah, MTA: Thank you for having me.

Topol: It's a real pleasure and this an important and critical topic. Your essay was "My Child Is Sick; Don't Call Her a 'Consumer.'"[1] There is so much to learn here for Medscape folks. Can you tell us a little bit about your background and your family?

Durrah: Sure. I am a patient/family engagement consultant by profession, which basically means that I work with healthcare organizations and systems around the concept of patient/family engagement, spanning anywhere from patient-centered measurements to quality improvement, and so on. I came to the work, though, not as part of a plan, but by fate and destiny. My firstborn, whose name is Ayah, was born with a very rare liver disease which we knew would require liver transplantation. She is 16 years old now, but as you can imagine, we've been on quite a journey in the healthcare system. In addition, I have four other children and my husband is an adult medical hospitalist at a major academic center on the East Coast, so healthcare is a big piece of our lives.

I realized a few years into the journey with my daughter that I wanted to become more engaged in improving healthcare and partnering with our care teamthe physicians, nurses, pharmacists, and the larger group of specialists that she was seeing on a regular basis. I had the opportunity to volunteer at a local hospital that was looking for more patient/family involvement in some of their quality improvement work, and I decided that this was definitely something I wanted to pursue further, so I did. But my daughter's healthcare journey continues and I continue to see the good, the not so good, and everything in between.

In addition, I think I have a unique perspective because my husband is a physician and works in the hospital setting. I understand and can empathize with the real challenges facing physicians that are constantly placing pressure on them and demanding their time. I am very cognizant of that, so in my work I really try to balance the voice of the patient or caregiver, and the voice of the physician or nurse, because I can definitely see all of the different perspectives. At the end of the day, I think we all really want these meaningful relationships where we communicate and empathize with one another, and at the same time, we all want the best care for each other. That is my goal and the work I've been doing for the past several years.

Topol: That is terrific. You have a panoramic view of the healthcare landscapethat's for sure.

Topol: You wrote about your daughter; it is a miracle story in so many respects. Her name, Ayah, means "sign of God"is that right?

Durrah: Yes. We named her that before I knew she was going to be born with this illness, and it's pretty remarkable that she fit that name and the meaning of her name since she was born. Her first liver transplant, unfortunately, failed within the first 24 hours. As you all know, a liver does not wait, so we were preparing to say goodbye to her when she was about 5 years old.

Subsequently, by miracle, she got another liver 2 days later. It was from the same hospital where she was at, which was even more amazing because her surgeons were prepared to travel anywhere to get another liver. She was placed number one on the nation live listing after that first transplant failed, and it's remarkable that she got another one.

Topol: After she had these two liver transplants at age 5, she got Burkitt lymphoma.

Durrah: Unfortunately, because of her therapies, and also being Epstein-Barr viruspositive, she developed stage III Burkitt lymphoma 2 years after the liver transplant, which was quite devastating, to say the least.

Topol: It required another type of transplant, a bone marrow transplant.

Durrah: Yes. Unfortunately, she had several months of a pretty intense chemotherapy regimen that ultimately failed, and we had to move to an autologous bone marrow transplant. She was not able to have donor cells because she was already an organ transplant recipient. She sat one day in the hospital with a catheter, and they took her stem cells and then gave them back to her about a month later after some more intense chemotherapy.

In all our experiences, I don't believe that physicians and nurses ever defined my daughter as a consumer.

Obviously, she has been through quite a bit. A lot goes along with being a patient of liver disease or a patient who survived cancer with all of the chemotherapy, so while her health is stable, things are constantly moving in the background that we're watching. I tell people that I sometimes look at it like a radar screen. You kind of see the little red dots bleeping and some of them get brighter and some of them get dimmer. A lot of people are monitoring those lights, but I'm the chief monitor of all of those lights and the coordinator of making sure we stay on top of them.

Topol: You are quite an advocate and it is just an amazing story. I want to get into this message that you have about using the term "consumer," because I have hated that term for years. Why do we use this term when we're talking about patients in the health world? You wrote, "I share our story because I am becoming increasingly troubled by a trend in healthcaretoward thinking of patients as 'consumers' but not actually engaging communities in healthcare improvement and innovation." Tell us a bit about this objection of this term, because I think if anybody has a right to object to the use of that term, it would be you.

Durrah: The term definitely does not resonate with me, and I share your strong feelings against the utilization of this term. Overall, I think it continues to underline and push the business imperative of healthcare versus the humanity imperative in which healthcare was initially built upon. I reject in some ways that this notion of consumerism will improve healthcare because healthcare did not start as a business imperative, nor was the framework built to support such a term.

In all of our experiences, I don't believe that physicians and nurses ever defined my daughter as a consumer. I believe [the term] distances us from one another and does not amplify or support that relationship-based care that we all seek to have and to improve. I also don't think "consumer" empowers us, although I understand why some believe it may, because the framework of healthcare is not set up in such a way where "consumer" denotes choice. A lot of healthcare is dictated to the patient or to the caregivers by their insurance companies or their lack thereof, or the communities in which they live, or by lots of different other parties that are involved in it. I'm not quite sure where the choice comes in, especially because no one chooses to be sick. A consumer has choices, but we don't have that choice.

It does not make sense to use that term. I understand where people come from wanting to empower individuals by changing the terminology [to a less] "passive" role of the patient, but I'm not quite sure that changing the terminology we use makes us equals, gives us any more choices, or improves the care we will receive.

Topol: Words are important. This term is hackneyed, it's pervasive, and I think you made the most eloquent case in the history of the medical literature because your intersection with the healthcare world is extensive.

Durrah: Oh my gosh. I'm humbled by that. I'm not sure if I deserve all that, but I appreciate it.

Topol: You have a master's degree from George Washington and you worked in tourism, and you made some interesting parallels between a consumer of tourism versus a patient. Can you talk to us about that?

Durrah: Sure. My master's is in tourism and administration, with a focus in meeting and event management, and here I am in healthcare advocacy now. But I found that it's been very useful because you do see in healthcare this shift of trying to create a tourism-type experience for healthcare. And generally speaking, tourism is a choice; we all choose to travel or to use a certain hotel or rental car company because we've had experiences. Most of the time, you come back from a vacation with great memories, and when you share those memories with others, they may want to have the same experiences as you.

But I don't believe that we can really equate healthcare to a vacation. I'm not quite sure who would utilize that same experience as a vacation. Things that healthcare has that no other industry has are the trauma, pain, and anguish that go into being either a patient or the caregiver of someone. I think physicians and nurses have a lot of emotions in the healthcare experience that you could never find in tourism. And tourism tries to have a constant feedback loop with their customers or consumers; healthcare does not. Yes, we tout these wonderful surveys that are supposed to increase patient satisfaction, but were any of them co-designed with the communities the health systems serve? The answer is no. Do they allow you to really respond in such a way that will provide meaningful data using stories of your experiences in the system? No. So again, trying to equate the healthcare experience with the lessons learned from tourism is a mismatch.

Topol: Right. Even that term "medical tourism" is about a different concept.

There are many parts of your daughter's story that were really touching and deep, but one of the things that stood out was how her liver doctor would hold your hand, and how that was not about consumerism but, as you say, a choice driven by humanity and compassion. This, I think, speaks to the stark dramatic differences between the terms.

Topol: Another term I'm interested in asking you about is "providers." It's another term I don't care for. Should that term be used?

Durrah: It's interesting, because I believe that in the article I do reference "care providers" at one point. Initially when I started in this work, I always [used the specific terms of] "physicians," "nurses," "pharmacists," and so on. All of a sudden that term "provider" got thrown into the mix, and I adapted it because it seemed that everyone was using it to cover all the members of the care team that might interact or touch a patient. I'm guilty of using that term and I got a lot of response after my article came out, particularly from physicians, about how the term "provider" was not liked. I believe the term came about with this whole business imperative/push in healthcare. Insurance companies use that term and healthcare systems have now adopted that term as well, and it probably is in play because of this whole consumerism push as well.

I did prefer saying "physicians" or "nurses" or "pharmacists" and that we're all part of the "care team." I prefer that terminology, just as I prefer to be called a "partner" in my care versus a "consumer" or a "customer." I think that the term does not fit the role that physicians and nurses play. They are not just a provider. I look at them as part of my team and I'm on their team, so we're all working together. I think "provider" also sounds a little bit like a hierarchy. It does not suggest that notion of that partnership and just reinforces a distance. Consumerism is kind of defined by this transactional relationship, so you would use that term to reinforce that. I see how it has developed and how it's being pushed, and I think it's all related to the business of medicine versus the actual human experience and the humanity of medicine.

We so largely lost the 'care' in 'healthcare.

Topol: These terms got adopted when healthcare was transformed to a business, and now we're relooking at this.

Your work and eloquence and what you continue to do as an advocate in patient care will help us get back on track. It's just one of many things we need to do.

Topol: You also brought up the term "lean principles." It would be interesting for you to just touch on this as well.

Durrah: I've noticed in my work in healthcare thus far that health systems are adopting a lot of frameworks. One of these is becoming "lean" or utilizing "lean principles," which are driven by efficiency and cost savings.

Typically, those who advocate for lean principles within health systems say, "This is going to benefit everyone: physicians, nurses, patients and families, and the communities we serve." But if you really dig down deep, I don't think it has trickled down at all to any cost savings for patients or families. I don't think it's improved quality for communities which the healthcare system serves. And I certainly don't see physicians and nurses not being more burned out or more extended. They get affected by lean principles, where staffing is cut in order for that cost savings to occur. They are being told to do 150 things versus 100 things a day.

When I first learned about "lean" and read about it, I thought it sounded great. But then when I got deeper into this work, I thought, "Wait a minutewho is this benefiting other than the bottom line of healthcare systems?" It's really interesting how healthcare tends to cherry-pick principles or terminology from other industries with the goal of trying to improve healthcare, when it's really not doing that. It's simply putting a Band-Aid on one problem and creating a new one.

Topol: We so largely lost the "care" in "healthcare." You referred to the "care team." You undoubtedly experienced that with your daughter, and we want to bring it back. We should be more precise about language and avoid business terms, and talk about clinicians as doctors, nurses, pharmacists, physical therapists, or whoever. We should be more specific than using this "provider" term which obviously could be a relative or a friend.

Topol: What response did you receive from the essay you wrote in Health Affairs? It clearly resonated, and when I posted it on Twitter, there was quite a bit of response.

Durrah: I got an incredible response from the article, and I appreciate you tweeting and retweeting it because a lot of people saw that and reached out to me and started retweeting as well. A number of people sent me personal emails and messages, and I really was humbled by the response. I was quite nervous to write the article I did because in my work, there is kind of a fine line that you can only push the boundary so far, and then if you push them too far you get a lot of pushback. I sometimes feel like I'm this one little patient advocate voice among all these other voices. The article really resonated with physicians in particular, and they really understood the story which I shared about my daughter's liver doctor.

When we found out that she was diagnosed with cancer, she asked to sit in the meeting with the oncologists. She didn't have to do that, but she wanted to. I said, "Of course you can join us." She sat next to me and held my hand the entire meeting. Every time they said something distressing, she would just squeeze my hand, but she didn't utter a word. I think that encapsulates the relationship that patients and caregivers have with their physician or nurse. It's such a special bond, and the term "consumer" could never define that particular bond; she would never look at this as a transactional relationship. Would "consumer" teach her to do that? No. As you said before, it is the humanity and compassion of medicine, and that is why most everyone who comes into the profession really wants to help humanity and give that empathy and compassion.

We have a lot to learn, and it's going to take many voices to speak up and push back against consumerism because some pretty large organizations and groups are trying to push consumerism and continue this business imperative of healthcare that is motivated by bottom lines. I think we're going to get there. Maybe we're already there. We're at a tipping point. There is so much dissatisfaction, and so many parts of the system are broken. To say that consumerism will give you more choices, shorter wait times, and maybe even price transparency, even though you still have to deal with your insurance provider or lack thereof, makes me giggle because I don't think that is going to be the solution.

The only solution I see is that we have to partner with one another and co-create solutions to improve healthcare as teamsequal voices at the tableand begin this pushback. If we don't, I fear what is ahead because I've already had a glimpse of it. I'm nervous because as my daughter slowly moves into adulthood, and she is almost there, these were the things I hoped we would have conquered before she got to that point. A lot of this is pushing us away from one another and distancing ourselves from one another, and that is not going to change healthcare.

Topol: You said it so well. I've been eager to meet you since I read your work months ago, and I wanted the whole Medscape audience to get to know you and your story. Most of them are not on Twitter and most don't read Health Affairs. Your story is so darn important, and you convey it in a powerful way.

I'm so glad to know that your daughter is okay, having gone through 16 years of rough times, especially in her earlier years. I just want you to carry on. You are an important voice. You may qualify yourself as only one, but it's a powerful one, and very few people have had an experience like yours. You're in a rarified group and can transmit the emotion and the sense of caring. Let's get these words right, and let's zap "consumer" from this story of future healthcare.

Thanks so much for joining us today on Medscape, and we will look forward to following you and learning more from you in the future.

Durrah: Thank you. I look forward to partnering with your audience on improving healthcare.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

Read more here:
Healthcare Terms Are Out of Touch, Says Mom Advocate - Medscape

ISCT forms cell and gene therapy sector-wide coalition to combat the rise of unproven commercial cell banking services – PharmiWeb.com

Vancouver, Canada, October 21, 2019 ISCT, the International Society for Cell and Gene Therapy, the global professional society of clinicians, researchers, regulatory specialists, technologists and industry partners in the cell and gene therapy sector, today announces it has formed a global consortium of a wide range of leading professional and education societies to combat the rise in the number of unproven commercial cell banking services. Full details of the statement can be foundhere.

The consortium partners include the International Society for Stem Cell Research (ISSCR), Society for Immunotherapy of Cancer (SITC), American Society for Transplantation and Cellular Therapy (ASTCT),American Society of Gene & Cell Therapy (ASGCT), European Society for Blood and Marrow Transplantation (EBMT), Foundation for the Accreditation of Cellular Therapy (FACT), Joint Accreditation Committee ISCT-EBMT (JACIE) and the Forum for Innovative Regenerative Medicine (FIRM).

The consortium has been formed following ISCT issuingpatient advice and concern on unproven T-cell preservation services on August 7, 2019. These services include the banking of T-cells, dental cells and cells for the derivation of induced pluripotent stem cells for potential therapeutic uses.

The joint statement from ISCT and the consortium partners includes an agreement on a number of key points. Commercial cell banking services are not supported by current scientific evidence, as opposed to the range of cell therapies such as CAR-T therapies, that follow established approval processes. Additionally, cell banking services cannot claim to know that the cells they preserve today could ever be appropriate for clinical use, could be used by manufacturers, or meet the requirements of many national and international regulatory agencies. As a result, there is no clear pathway to legitimate clinical use. All parties agree offering these services commercially to patients is thus premature, misleading, and drives false hope.

In addition, the ISCT joint statement makes clear that patients, being misled by these services, are thus prevented from giving a full and valid informed consent. Cell banking companies mislead patients in a number of ways, including using tokens of scientific legitimacy that suggest a stronger scientific basis than currently exists. These tokens include endorsements from individuals or scientific advisory boards that might not fully endorse the specific products, links to scientific articles, and references to ongoing clinical trials.

ISCTs raison detre is to lead the industry in supporting scientifically validated cell and gene therapies. As a result, ISCT will continue to welcome all innovations, including cell banking approaches, that increase the number of patients who can benefit from these therapies, said Bruce Levine,President-Elect, ISCT and one of the inventors of CAR-T therapies.However, ISCT also leads industry action on unproven cell therapies and services in the cell and gene sector. This is why ISCT has forged a consortium throughout the industry against the marketing of speculative cell banking services that do not have appropriate pre-clinical, and clinical evidence and a plausible pathway to the clinical use of banked cells. We collectively believe these banks have the potential to be detrimental to the future development of cell and gene therapies.

About ISCT

Established in 1992, ISCT, the International Society for Cell and Gene Therapy is a global society of clinicians, regulators, researchers, technologists and industry partners with a shared vision to translate cellular therapy into safe and effective therapies to improve patients lives worldwide.

ISCT is the global leader focused on pre-clinical and translational aspects of developing cell-based therapeutics, thereby advancing scientific research into innovative treatments for patients. ISCT offers a unique collaborative environment that addresses three key areas of translation: Academia, Regulatory and Commercialization. Through strong relationships with global regulatory agencies, academic institutions and industry partners, ISCT drives the advancement of research into standard of care.

Comprised of over 1,500 cell therapy experts across five geographic regions and representation from over 50 countries, ISCT members are part of a global community of peers, thought leaders and organizations invested in cell therapy translation. For more information about the society, key initiatives and upcoming meetings, please visit:

Read the rest here:
ISCT forms cell and gene therapy sector-wide coalition to combat the rise of unproven commercial cell banking services - PharmiWeb.com

Artificial embryo without sperm or egg forms live fetus – ZME Science

For the very first time, scientists have made artificial embryos from scratch, without sperm or egg, and implanted them into female mice. The embryos developed into live fetuses, but these exhibited major malformations.

The team at the University of Texas Southwestern Medical Center used extended pluripotent stem cells, which are cells that have the potential, like an embryo, to develop into any type of tissue in the body. These master cells are able to form all three major types of cell groups (ectoderm, endoderm, and mesoderm). Unlike simple pluripotent stem cells, the extended variety can develop into tissues that support the embryo, such as the placenta.Without this type of stem cells, embryos cannot develop and grow properly.

The researchers coaxed stem cells to form into all the cells required for the development of an embryo by bathing them into a solution made of nutrients, growth stimulants, and signaling molecules. The cells assembled into embryo-like structures, including placental tissue.

Next, the artificial embryos were implanted into the uteruses of female mice. Only 7% of the implants were successful but those embryos that did work actually started developing early fetal structures. There were major malformations, however, as the tissue structure and organization did not closely resemble that of a normal embryo.

Previously, other research groups had managed to grow artificial embryos but this was the first time that they were successfully implanted and developed placental cells.

In the future, the University of Texas researchers plan on refining their method in order to grow fetuses that are indistinguishable from normal ones. The goal is to replace real embryos and make artificial ones at scale. These embryo models could then be grown in dishes to study early mammalian development and accelerate drug development.

Some of the cells that the researchers used to grow into embryos originally came from the ear of a mouse. Theoretically, the same should be possible for human embryos, but why would we? Besides testing drugs, artificial embryos could be grown from the skin cells of an infertile person. Then, in the lab, these embryos could be studied in order to identify potential genetic defects that might cause infertility.

Even if such stem cell-derived embryos do not completely mimic normal embryo growth, there is still a lot we can learn about mammalian development. But, as is always the case with research that breaks the frontiers of what was once thought possible, our policies havent yet kept up with advances. There are serious ethical considerations to possibly making a person from a synthetic embryo. Although such a prospect is still science fiction, rapid developments such as the present study suggest that it is not impossible and we better prepare.

The findings were reported in the journal Cell.

Read more from the original source:
Artificial embryo without sperm or egg forms live fetus - ZME Science

CRISPR Therapeutics and KSQ Therapeutics Announce License Agreement to Advance Companies’ Respective Cell Therapy Programs in Oncology – Business Wire

ZUG, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and KSQ Therapeutics, a biotechnology company using CRISPR technology to enable the companys powerful drug discovery engine to achieve higher probabilities of success in drug development, today announced a license agreement whereby CRISPR Therapeutics will gain access to KSQ intellectual property (IP) for editing certain novel gene targets in its allogeneic oncology cell therapy programs, and KSQ will gain access to CRISPR Therapeutics IP for editing novel gene targets identified by KSQ as part of its current and future eTILTM (engineered tumor infiltrating lymphocyte) cell programs. The financial terms of the agreement are not being disclosed.

We are thrilled to gain access to CRISPR Therapeutics foundational IP estate through this agreement, said David Meeker, M.D., Chief Executive Officer at KSQ Therapeutics. Our eTILTM programs involve editing gene targets in human TILs that were discovered at KSQ by applying our proprietary CRISPRomics approach to immune cells in multiple in vivo models. This agreement clears an important path for us to be able to bring these programs through development and commercialization, leveraging CRISPR Therapeutics proprietary editing technology.

The gene targets within the scope of the license agreement were identified using KSQs proprietary CRISPRomics drug discovery engine, which allows genome-scale, in vivo validated, unbiased drug discovery. These specific targets were uncovered in screens to identify genetic edits that could enhance the functionality and quality of adoptive cell therapies in oncology.

KSQ has built an industry-leading platform to screen for novel gene targets using its technology, and has identified a group of targets that could help unlock the full potential of adoptive cell therapy in oncology, said Samarth Kulkarni, Ph.D., Chief Executive Officer at CRISPR Therapeutics. As a result of this license agreement, CRISPR Therapeutics will have the opportunity to bring these novel targets into our leading allogeneic CAR-T development platform to further strengthen our future programs in this important therapeutic area.

About KSQ Therapeutics

KSQ Therapeutics is using CRISPR technology to enable the companys powerful drug discovery engine to achieve higher probabilities of success in drug development. The company is advancing a pipeline of tumor- and immune-focused drug candidates for the treatment of cancer, across multiple drug modalities including targeted therapies, adoptive cell therapies and immuno-therapies. KSQs proprietary CRISPRomics drug discovery engine enables genome-scale, in vivo validated, unbiased drug discovery across broad therapeutic areas. KSQ was founded by thought leaders in the field of functional genomics and pioneers of CRISPR screening technologies, and the company is located in Cambridge, Massachusetts. For more information, please visit the companys website at http://www.ksqtx.com.

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer AG, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in London, United Kingdom. For more information, please visit http://www.crisprtx.com.

CRISPR Therapeutics Forward-Looking Statement

This press release may contain a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding CRISPR Therapeutics expectations about any or all of the following: (i) the intellectual property coverage and positions of CRISPR Therapeutics, its licensors and third parties and (ii) the therapeutic value, development, and commercial potential of CRISPR/Cas9 gene editing technologies and therapies. Without limiting the foregoing, the words believes, anticipates, plans, expects and similar expressions are intended to identify forward-looking statements. You are cautioned that forward-looking statements are inherently uncertain. Although CRISPR Therapeutics believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: the outcomes for each CRISPR Therapeutics planned clinical trials and studies may not be favorable; that one or more of CRISPR Therapeutics internal or external product candidate programs will not proceed as planned for technical, scientific or commercial reasons; that future competitive or other market factors may adversely affect the commercial potential for CRISPR Therapeutics product candidates; uncertainties inherent in the initiation and completion of preclinical studies for CRISPR Therapeutics product candidates; availability and timing of results from preclinical studies; whether results from a preclinical trial will be predictive of future results of the future trials; uncertainties about regulatory approvals to conduct trials or to market products; uncertainties regarding the intellectual property protection for CRISPR Therapeutics technology and intellectual property belonging to third parties; and those risks and uncertainties described under the heading "Risk Factors" in CRISPR Therapeutics most recent annual report on Form 10-K, and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission, which are available on the SEC's website at http://www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. CRISPR Therapeutics disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

More:
CRISPR Therapeutics and KSQ Therapeutics Announce License Agreement to Advance Companies' Respective Cell Therapy Programs in Oncology - Business Wire